Nanjing King-friend Biochemical Pharmaceutical Co Ltd
SSE:603707
Income Statement
Earnings Waterfall
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Revenue
|
4B
CNY
|
Cost of Revenue
|
-2B
CNY
|
Gross Profit
|
2B
CNY
|
Operating Expenses
|
-904.7m
CNY
|
Operating Income
|
1.1B
CNY
|
Other Expenses
|
-34.2m
CNY
|
Net Income
|
1B
CNY
|
Income Statement
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||||||||||||||
Revenue |
758
N/A
|
915
+21%
|
1 113
+22%
|
1 325
+19%
|
1 479
+12%
|
1 633
+10%
|
1 700
+4%
|
1 875
+10%
|
2 027
+8%
|
2 224
+10%
|
2 470
+11%
|
2 594
+5%
|
2 689
+4%
|
2 800
+4%
|
2 915
+4%
|
3 064
+5%
|
3 270
+7%
|
3 537
+8%
|
3 687
+4%
|
3 980
+8%
|
3 911
-2%
|
3 758
-4%
|
3 713
-1%
|
3 844
+4%
|
4 041
+5%
|
4 004
-1%
|
|
Gross Profit | |||||||||||||||||||||||||||
Cost of Revenue |
(438)
|
(504)
|
(597)
|
(716)
|
(771)
|
(850)
|
(860)
|
(945)
|
(1 008)
|
(1 092)
|
(1 204)
|
(1 213)
|
(1 176)
|
(1 186)
|
(1 236)
|
(1 251)
|
(1 392)
|
(1 523)
|
(1 603)
|
(1 834)
|
(1 826)
|
(1 796)
|
(1 778)
|
(1 866)
|
(2 024)
|
(2 042)
|
|
Gross Profit |
320
N/A
|
411
+29%
|
516
+26%
|
609
+18%
|
707
+16%
|
784
+11%
|
840
+7%
|
929
+11%
|
1 019
+10%
|
1 132
+11%
|
1 265
+12%
|
1 380
+9%
|
1 513
+10%
|
1 614
+7%
|
1 679
+4%
|
1 813
+8%
|
1 879
+4%
|
2 013
+7%
|
2 083
+3%
|
2 146
+3%
|
2 085
-3%
|
1 961
-6%
|
1 935
-1%
|
1 977
+2%
|
2 017
+2%
|
1 962
-3%
|
|
Operating Income | |||||||||||||||||||||||||||
Operating Expenses |
(112)
|
(113)
|
(175)
|
(203)
|
(259)
|
(325)
|
(390)
|
(440)
|
(503)
|
(557)
|
(594)
|
(637)
|
(684)
|
(733)
|
(758)
|
(811)
|
(812)
|
(843)
|
(854)
|
(839)
|
(834)
|
(822)
|
(913)
|
(929)
|
(990)
|
(905)
|
|
Selling, General & Administrative |
(112)
|
(112)
|
(87)
|
(179)
|
(237)
|
(265)
|
(283)
|
(347)
|
(377)
|
(419)
|
(420)
|
(465)
|
(493)
|
(541)
|
(551)
|
(592)
|
(582)
|
(604)
|
(614)
|
(597)
|
(603)
|
(592)
|
(611)
|
(641)
|
(671)
|
(580)
|
|
Research & Development |
0
|
0
|
(77)
|
(25)
|
0
|
(59)
|
(90)
|
(87)
|
(125)
|
(138)
|
(148)
|
(178)
|
(187)
|
(189)
|
(143)
|
(174)
|
(188)
|
(197)
|
(183)
|
(241)
|
(231)
|
(229)
|
(219)
|
(278)
|
(309)
|
(315)
|
|
Depreciation & Amortization |
0
|
0
|
(11)
|
0
|
0
|
0
|
(17)
|
0
|
0
|
0
|
(25)
|
0
|
0
|
0
|
(61)
|
0
|
0
|
0
|
(55)
|
0
|
0
|
0
|
(82)
|
0
|
0
|
0
|
|
Other Operating Expenses |
(1)
|
(1)
|
(0)
|
1
|
(23)
|
(1)
|
(1)
|
(6)
|
(1)
|
1
|
(1)
|
6
|
(4)
|
(4)
|
(3)
|
(45)
|
(42)
|
(42)
|
(2)
|
(1)
|
(0)
|
(1)
|
(2)
|
(10)
|
(10)
|
(10)
|
|
Operating Income |
208
N/A
|
298
+44%
|
341
+14%
|
406
+19%
|
448
+10%
|
459
+2%
|
451
-2%
|
489
+9%
|
517
+6%
|
576
+11%
|
672
+17%
|
744
+11%
|
829
+11%
|
880
+6%
|
921
+5%
|
1 002
+9%
|
1 067
+6%
|
1 170
+10%
|
1 229
+5%
|
1 307
+6%
|
1 251
-4%
|
1 140
-9%
|
1 021
-10%
|
1 048
+3%
|
1 028
-2%
|
1 057
+3%
|
|
Pre-Tax Income | |||||||||||||||||||||||||||
Interest Income Expense |
6
|
13
|
12
|
19
|
17
|
8
|
10
|
1
|
7
|
6
|
(4)
|
(11)
|
(25)
|
(40)
|
(44)
|
(56)
|
(22)
|
(1)
|
(46)
|
(41)
|
29
|
132
|
153
|
117
|
148
|
2
|
|
Non-Reccuring Items |
0
|
0
|
0
|
(0)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(1)
|
0
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
Gain/Loss on Disposition of Assets |
0
|
(0)
|
(0)
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
5
|
4
|
4
|
4
|
5
|
6
|
7
|
12
|
12
|
11
|
13
|
9
|
11
|
31
|
38
|
47
|
47
|
23
|
22
|
13
|
2
|
8
|
12
|
12
|
33
|
33
|
|
Pre-Tax Income |
218
N/A
|
314
+44%
|
356
+13%
|
429
+20%
|
470
+10%
|
473
+1%
|
468
-1%
|
502
+7%
|
535
+7%
|
593
+11%
|
680
+15%
|
741
+9%
|
815
+10%
|
871
+7%
|
915
+5%
|
993
+9%
|
1 091
+10%
|
1 193
+9%
|
1 204
+1%
|
1 280
+6%
|
1 280
+0%
|
1 278
0%
|
1 185
-7%
|
1 177
-1%
|
1 208
+3%
|
1 092
-10%
|
|
Net Income | |||||||||||||||||||||||||||
Tax Provision |
(25)
|
(38)
|
(42)
|
(49)
|
(52)
|
(48)
|
(43)
|
(50)
|
(49)
|
(55)
|
(74)
|
(80)
|
(91)
|
(104)
|
(118)
|
(127)
|
(147)
|
(160)
|
(140)
|
(159)
|
(157)
|
(155)
|
(99)
|
(89)
|
(111)
|
(71)
|
|
Income from Continuing Operations |
193
|
276
|
314
|
380
|
418
|
425
|
425
|
452
|
487
|
539
|
606
|
661
|
724
|
767
|
797
|
866
|
944
|
1 033
|
1 064
|
1 121
|
1 123
|
1 123
|
1 087
|
1 088
|
1 098
|
1 021
|
|
Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
0
|
3
|
10
|
9
|
9
|
5
|
(5)
|
(5)
|
(5)
|
(2)
|
4
|
5
|
4
|
2
|
|
Net Income (Common) |
193
N/A
|
276
+43%
|
314
+14%
|
380
+21%
|
418
+10%
|
425
+2%
|
425
0%
|
452
+6%
|
487
+8%
|
539
+11%
|
605
+12%
|
660
+9%
|
724
+10%
|
770
+6%
|
806
+5%
|
875
+9%
|
953
+9%
|
1 038
+9%
|
1 059
+2%
|
1 116
+5%
|
1 118
+0%
|
1 122
+0%
|
1 091
-3%
|
1 093
+0%
|
1 101
+1%
|
1 023
-7%
|
|
EPS (Diluted) |
0.23
N/A
|
0.32
+39%
|
0.37
+16%
|
0.42
+14%
|
0.45
+7%
|
0.46
+2%
|
0.46
N/A
|
0.49
+7%
|
0.53
+8%
|
0.58
+9%
|
0.65
+12%
|
0.71
+9%
|
0.78
+10%
|
0.83
+6%
|
0.86
+4%
|
0.93
+8%
|
0.6
-35%
|
0.61
+2%
|
0.68
+11%
|
0.7
+3%
|
0.69
-1%
|
0.7
+1%
|
0.67
-4%
|
0.68
+1%
|
0.68
N/A
|
0.63
-7%
|